Transcription of HEALTH PRODUCTS MENTIONED IN THIS ISSUE
{{id}} {{{paragraph}}}
Example: air traffic controller
HEALTH PRODUCTS MENTIONED IN THIS ISSUE
December 2021. HEALTH PRODUCTS MENTIONED IN THIS ISSUE . Pharmaceuticals and biologics Lucentis (ranibizumab injection). CONTENTS lupron and lupron Depot (leuprolide acetate). Coronavirus disease (COVID-19) 2 Mylotarg (gemtuzumab ozogamicin). Monthly recap 2 Selective serotonin reuptake inhibitors New information Serotonin-norepinephrine reuptake inhibitors Review article Verkazia (cyclosporine). Atypical hemolytic reactions following exposure to gemtuzumab ozogamicin Natural and non-prescription HEALTH PRODUCTS (Mylotarg) 3 Odor-Eaters Spray Powder Product monograph updates TUMS Assorted Berries Extra Strength Tablets lupron and lupron Depot (leuprolide acetate) 5 Other Selective serotonin reuptake inhibitors Unauthorized HEALTH PRODUCTS (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) 5. Notice of market authorization with conditions Lucentis (ranibizumab injection) 6.
Lupron and Lupron Depot (leuprolide acetate) The Warnings and Precautions, Adverse Reactions (Post-market Adverse Drug Reactions), and Patient Medication Information sections of the Canadian product monograph for Lupron and Lupron Depot have been updated with the risk of pseudotumor cerebri/idiopathic intracranial hypertension in pediatric patients
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: